DK3909972T5 - Pd1-cd28-fusionsproteiner og disses anvendelse i medicin - Google Patents
Pd1-cd28-fusionsproteiner og disses anvendelse i medicin Download PDFInfo
- Publication number
- DK3909972T5 DK3909972T5 DK21155542.0T DK21155542T DK3909972T5 DK 3909972 T5 DK3909972 T5 DK 3909972T5 DK 21155542 T DK21155542 T DK 21155542T DK 3909972 T5 DK3909972 T5 DK 3909972T5
- Authority
- DK
- Denmark
- Prior art keywords
- medicine
- fusion proteins
- fusion
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15172913 | 2015-06-19 | ||
| EP16736802.6A EP3310805B1 (en) | 2015-06-19 | 2016-06-20 | Pd-1-cd28 fusion proteins and their use in medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3909972T3 DK3909972T3 (da) | 2024-04-29 |
| DK3909972T5 true DK3909972T5 (da) | 2024-08-05 |
Family
ID=53476720
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21155542.0T DK3909972T5 (da) | 2015-06-19 | 2016-06-20 | Pd1-cd28-fusionsproteiner og disses anvendelse i medicin |
| DK16736802.6T DK3310805T3 (da) | 2015-06-19 | 2016-06-20 | Pd-1-cd28-fusionsproteiner og anvendelse deraf i medicin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16736802.6T DK3310805T3 (da) | 2015-06-19 | 2016-06-20 | Pd-1-cd28-fusionsproteiner og anvendelse deraf i medicin |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11192935B2 (enExample) |
| EP (3) | EP3909972B1 (enExample) |
| JP (3) | JP7085988B2 (enExample) |
| CN (3) | CN115927474A (enExample) |
| AU (1) | AU2016277883B2 (enExample) |
| CA (1) | CA2989949A1 (enExample) |
| DK (2) | DK3909972T5 (enExample) |
| ES (2) | ES2870174T3 (enExample) |
| FI (1) | FI3909972T3 (enExample) |
| HU (1) | HUE054201T2 (enExample) |
| PL (1) | PL3310805T3 (enExample) |
| PT (1) | PT3310805T (enExample) |
| WO (1) | WO2016203048A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201707182WA (en) | 2015-03-05 | 2017-10-30 | Hutchinson Fred Cancer Res | Immunomodulatory fusion proteins and uses thereof |
| EP3770168A1 (en) | 2015-05-18 | 2021-01-27 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| PT3310805T (pt) * | 2015-06-19 | 2021-05-19 | Kobold Sebastian | Proteínas de fusão pd-1-cd28 e a sua utilização em medicina |
| MX2018000278A (es) * | 2015-06-29 | 2018-03-08 | Univ Johns Hopkins | Terapia de receptores quimericos de puntos de control inmunitarios. |
| CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| US11365237B2 (en) * | 2016-03-23 | 2022-06-21 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Fusion proteins of PD-1 and 4-1BB |
| CN107523545A (zh) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的杀伤性细胞及其用途 |
| EP3478722A1 (en) * | 2016-06-30 | 2019-05-08 | F. Hoffmann-La Roche AG | Improved adoptive t-cell therapy |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| CA3047999A1 (en) * | 2016-12-21 | 2018-06-28 | TCR2 Therapeutics Inc. | Engineered t cells for the treatment of cancer |
| US11535662B2 (en) * | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
| US11725210B2 (en) | 2017-03-17 | 2023-08-15 | Fred Hutchinson Cancer Center | Immunomodulatory fusion proteins and uses thereof |
| KR20200130709A (ko) * | 2018-03-06 | 2020-11-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 전립선-특이 막 항원 car 및 이의 사용 방법 |
| CN108727504B (zh) * | 2018-04-16 | 2021-08-27 | 泉州向日葵生物科技有限公司 | 一种ifn与抗pd-l1抗体的融合蛋白及其应用 |
| CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
| TW202042824A (zh) | 2019-03-27 | 2020-12-01 | 賓夕法尼亞大學董事會 | Tn-MUC1嵌合抗原受體（CAR）T細胞療法 |
| EP3999079A4 (en) * | 2019-07-19 | 2024-04-03 | Memorial Sloan Kettering Cancer Center | Fusion polypeptide for immunotherapy |
| CN113832114A (zh) * | 2020-06-23 | 2021-12-24 | 南京大学 | 一种新型溶瘤腺病毒EM/VSV-G Ad5-P及其在制备抗肿瘤药物中的应用 |
| CN113832111A (zh) * | 2020-06-23 | 2021-12-24 | 南京大学 | 一种类外泌体技术用于制备新型溶瘤病毒的方法 |
| EP4305174A4 (en) * | 2021-03-10 | 2025-04-30 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | REPORTER CELLS EXPRESSING CHIMERIC POLYPEPTIDES TO DETERMINE THE PRESENCE AND/OR ACTIVITY OF IMMUNE CHECKPOINT MOLECULES |
| CN115197314B (zh) * | 2021-04-11 | 2025-08-19 | 中国科学院分子细胞科学卓越创新中心 | 一种pd1变体及其用途 |
| JP2024519945A (ja) * | 2021-05-20 | 2024-05-21 | アチェロイス バイオファーマ，インク． | 免疫チェックポイント多価粒子の組成物、および使用方法 |
| WO2023235479A1 (en) * | 2022-06-02 | 2023-12-07 | TCR2 Therapeutics Inc. | Compositions and methods for treating cancer |
| EP4619424A2 (en) * | 2022-11-14 | 2025-09-24 | Achelois Biopharma, Inc. | Immune checkpoint multivalent particles compositions and methods of use |
| WO2025212859A1 (en) * | 2024-04-03 | 2025-10-09 | Solid Biosciences, Inc. | Methods and constructs for increasing solid organ transplant survival |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19822115B4 (de) | 1998-05-08 | 2004-04-08 | Heinrich-Pette-Institut | Retrovirale Gentransfervektoren |
| CN101287831B (zh) | 2005-09-13 | 2013-05-15 | 国立大学法人三重大学 | T细胞受体和编码该受体的核酸 |
| EP2318434A1 (en) | 2008-07-31 | 2011-05-11 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Her2/neu specific t cell receptors |
| ZA200807283B (en) | 2008-08-22 | 2009-10-28 | Mechlift Invest Pty Ltd | Data unit for a bin lifting device |
| AU2009290543B2 (en) | 2008-09-12 | 2015-09-03 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| CN103119054B (zh) * | 2010-03-26 | 2017-01-18 | 达特茅斯大学理事会 | Vista调节性t细胞介体蛋白、vista结合剂及其用途 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3459560B1 (en) | 2011-04-08 | 2021-02-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| MX2014001222A (es) * | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| JP6267644B2 (ja) | 2011-10-20 | 2018-01-24 | アメリカ合衆国 | 抗ｃｄ２２キメラ抗原受容体 |
| WO2013062365A2 (ko) * | 2011-10-26 | 2013-05-02 | 국립암센터 | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 |
| JP6074435B2 (ja) * | 2011-10-26 | 2017-02-01 | ナショナル キャンサー センター | 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物 |
| CA2868121C (en) | 2012-03-23 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| AU2013246443B2 (en) | 2012-04-11 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| JP6285553B2 (ja) | 2013-08-26 | 2018-02-28 | インノバイオファーム リミテッド | 抗ｃｄ３０キメラ抗原受容体およびその使用 |
| EP3227317A4 (en) | 2014-12-02 | 2018-04-25 | Roger Williams Hospital | Methods and compositons for treating cancer |
| SG11201707182WA (en) | 2015-03-05 | 2017-10-30 | Hutchinson Fred Cancer Res | Immunomodulatory fusion proteins and uses thereof |
| PT3310805T (pt) | 2015-06-19 | 2021-05-19 | Kobold Sebastian | Proteínas de fusão pd-1-cd28 e a sua utilização em medicina |
| JP6974311B2 (ja) | 2015-06-23 | 2021-12-01 | メモリアル スローン ケタリング キャンサー センター | 新規ｐｄ−１免疫調節剤 |
| MX2018000278A (es) | 2015-06-29 | 2018-03-08 | Univ Johns Hopkins | Terapia de receptores quimericos de puntos de control inmunitarios. |
| US11242375B2 (en) | 2015-09-04 | 2022-02-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| US11020429B2 (en) | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| CN105331585A (zh) | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| CN109072194B (zh) | 2015-12-09 | 2022-12-27 | 纪念斯隆-凯特林癌症中心 | 免疫细胞组合物及其使用方法 |
| US11365237B2 (en) | 2016-03-23 | 2022-06-21 | Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | Fusion proteins of PD-1 and 4-1BB |
| WO2018119198A1 (en) | 2016-12-22 | 2018-06-28 | Windmil Therapeutics, Inc. | Compositions and methods for modulating the immune system |
| CN111051349A (zh) | 2017-09-06 | 2020-04-21 | 弗雷德哈钦森癌症研究中心 | Strep-tag特异性嵌合受体及其用途 |
| CN115418362B (zh) * | 2019-12-02 | 2025-06-13 | 吉林凯莱英医药化学有限公司 | 共固定化酶、其制备方法及其应用 |
-
2016
- 2016-06-20 PT PT167368026T patent/PT3310805T/pt unknown
- 2016-06-20 CN CN202210834160.0A patent/CN115927474A/zh active Pending
- 2016-06-20 DK DK21155542.0T patent/DK3909972T5/da active
- 2016-06-20 FI FIEP21155542.0T patent/FI3909972T3/fi active
- 2016-06-20 ES ES16736802T patent/ES2870174T3/es active Active
- 2016-06-20 US US15/737,877 patent/US11192935B2/en active Active
- 2016-06-20 JP JP2018517487A patent/JP7085988B2/ja active Active
- 2016-06-20 EP EP21155542.0A patent/EP3909972B1/en active Active
- 2016-06-20 CN CN201680048221.3A patent/CN108026151B/zh active Active
- 2016-06-20 AU AU2016277883A patent/AU2016277883B2/en active Active
- 2016-06-20 CA CA2989949A patent/CA2989949A1/en active Pending
- 2016-06-20 CN CN202210854297.2A patent/CN115925971A/zh active Pending
- 2016-06-20 ES ES21155542T patent/ES2976647T3/es active Active
- 2016-06-20 WO PCT/EP2016/064195 patent/WO2016203048A1/en not_active Ceased
- 2016-06-20 EP EP24156660.3A patent/EP4349854A3/en active Pending
- 2016-06-20 EP EP16736802.6A patent/EP3310805B1/en active Active
- 2016-06-20 PL PL16736802T patent/PL3310805T3/pl unknown
- 2016-06-20 DK DK16736802.6T patent/DK3310805T3/da active
- 2016-06-20 HU HUE16736802A patent/HUE054201T2/hu unknown
-
2021
- 2021-10-29 US US17/515,250 patent/US12570718B2/en active Active
-
2022
- 2022-03-22 JP JP2022044885A patent/JP7460675B2/ja active Active
-
2024
- 2024-03-21 JP JP2024044396A patent/JP2024073636A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN108026151B (zh) | 2022-07-15 |
| CA2989949A1 (en) | 2016-12-22 |
| JP7085988B2 (ja) | 2022-06-17 |
| DK3909972T3 (da) | 2024-04-29 |
| JP2018518990A (ja) | 2018-07-19 |
| JP2024073636A (ja) | 2024-05-29 |
| CN115925971A (zh) | 2023-04-07 |
| AU2016277883B2 (en) | 2020-09-17 |
| EP4349854A3 (en) | 2024-07-10 |
| JP2022084787A (ja) | 2022-06-07 |
| ES2870174T3 (es) | 2021-10-26 |
| HUE054201T2 (hu) | 2021-08-30 |
| US20190010207A1 (en) | 2019-01-10 |
| EP4349854A2 (en) | 2024-04-10 |
| PL3310805T3 (pl) | 2021-08-23 |
| EP3909972B1 (en) | 2024-02-14 |
| AU2016277883A8 (en) | 2018-01-25 |
| JP7460675B2 (ja) | 2024-04-02 |
| CN108026151A (zh) | 2018-05-11 |
| WO2016203048A1 (en) | 2016-12-22 |
| EP3310805A1 (en) | 2018-04-25 |
| EP3909972A1 (en) | 2021-11-17 |
| EP3310805B1 (en) | 2021-02-17 |
| DK3310805T3 (da) | 2021-05-03 |
| US20220169699A1 (en) | 2022-06-02 |
| FI3909972T3 (fi) | 2024-05-03 |
| AU2016277883A1 (en) | 2018-01-18 |
| CN115927474A (zh) | 2023-04-07 |
| US11192935B2 (en) | 2021-12-07 |
| PT3310805T (pt) | 2021-05-19 |
| US12570718B2 (en) | 2026-03-10 |
| ES2976647T3 (es) | 2024-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3909972T3 (da) | Pd1-cd28-fusionsproteiner og disses anvendelse i medicin | |
| FIC20250034I1 (fi) | O-deuteroitu atropiini ja erityisesti O-deuteroidun atropiinin deuterohemisulfaattisuola | |
| DK3368555T3 (da) | Dobbeltfunktionsproteiner og farmaceutisk sammensætning omfattende disse | |
| DK3505519T3 (da) | Pyridinamin-substituerede heterotricyclo-forbindelser, fremstilling deraf og anvendelse i medicin | |
| IL262652A (en) | Gdf15 fusion proteins and uses thereof | |
| IL254165A0 (en) | Immunomodulatory fusion proteins and uses thereof | |
| SI3565828T1 (sl) | SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo | |
| DK3235830T3 (da) | Interleukin-15-proteinkompleks og anvendelse deraf | |
| DK3922279T3 (da) | Præparater til lægemiddelafgivelse og anvendelse heraf | |
| SI3328419T1 (sl) | PD-1-vezavne molekule in postopki uporabe le-teh | |
| DK3345587T3 (da) | Beholderholdeelement og medicinsk beholdersæt | |
| DK3378859T3 (da) | Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| DK3354282T3 (da) | Glycan-terapeutiske midler og relaterede fremgangsmåder deraf | |
| DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
| DK3354661T3 (da) | Fuldstændigt humant antistof mod human CD137 og anvendelse deraf | |
| DK3256218T3 (da) | Kdm1a-hæmmer og anvendelse deraf i terapi | |
| DK3368554T3 (da) | Langtidsvirkende fgf21-fusionsproteiner og farmaceutisk sammensætning omfattende samme | |
| SI3129018T1 (sl) | Zdravljenje nafld in nash | |
| SI3258951T1 (sl) | Anti-pvrig protitelesa in metode uporabe | |
| SI3116909T1 (sl) | Molekule protiteles na LAG-3 in njih uporaba | |
| DK3322734T3 (da) | Multivalente og multispecifikke DR5-bindende fusionsproteiner | |
| DK3368655T3 (da) | Forbedret proteinekspression og fremgangsmåder dertil | |
| SI3319612T1 (sl) | Oksisteroli in postopki za uporabo le-teh | |
| DK3275895T3 (da) | Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf |